# Health for Life Capital fund

> Health for Life Capital fund is a VC fund in Paris backing Biotechnology and Biopharma. See 8 investments, check sizes, portfolio. Updated Aug 2026.

- Type: VC Fund
- Location: Paris, France
- Total investments: 8
- Last investment: Jul 2021
- Lead investor: 0%
- Last updated: Aug 2026
- Website: https://www.seventure.fr/en/products/our-institutional-funds/

Health for Life Capital fund is a VC fund in Paris focused on Biotechnology and Biopharma. Health for Life Capital Fund is managed by Seventure Partners, which invests in the biotechnology and life science areas.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 5 | 63% |
| Biopharma | 3 | 38% |
| Medical | 2 | 25% |
| Pharmaceutical | 2 | 25% |
| Nutrition | 1 | 13% |

14 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series B | 2 | 25% |
| Series D | 2 | 25% |
| Series C | 1 | 13% |
| Series E | 1 | 13% |
| Funding Round | 1 | 13% |

6 stages tracked in total.

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 3 | 38% |
| Japan | 1 | 13% |
| France | 1 | 13% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Vedanta Biosciences | Vedanta Biosciences is a developer of immunotherapies designed to treat immune-mediated and infectious diseases. The company's immunotherapies include a suite of proprietary assays to select pharmacologically potent strains, vast proprietary datasets from human interventional studies, and facilities for cGMP-compliant manufacturing ofrationally-defined bacterial consortia in powder form, enabling physicians to access live bacteria drug to treat autoimmune and inflammatory diseases easily.It was founded in 2010 and is headquartered in Cambridge, Massachusetts. | $68M | Series D | Jul 21, 2021 |  |
| ENTEROME | Enterome is an integrated company leveraging its unique knowledge of the key functional and molecular interactions between the gut microbiome and the human body to develop targeted therapeutics.Enterome is focused on the identification of the bioactive molecules that are differentially expressed, secreted and regulated by the gut microbiome, whichplay a central role in the regulation of key aspects of human physiology and the immune system. | $51.9M | Series E | Jun 25, 2020 |  |
| Vertero | Axial Therapeutics is a clinical stage biopharmaceutical company harnessing the gut-brain axis to develop novel Central Nervous System (CNS) Therapeutics to improve the quality of life for people with CNS diseases and disorders. | $25M | Series B | Feb 27, 2019 |  |
| ENTEROME | Enterome is an integrated company leveraging its unique knowledge of the key functional and molecular interactions between the gut microbiome and the human body to develop targeted therapeutics.Enterome is focused on the identification of the bioactive molecules that are differentially expressed, secreted and regulated by the gut microbiome, whichplay a central role in the regulation of key aspects of human physiology and the immune system. | $43.9M | Debt Financing | Jan 04, 2018 |  |
| MycoTechnology | MycoTechnology utilizes fungi-based food-processing platforms to transform the flavor and value of agricultural products. The platform can be used to solve a variety of challenges faced by the food, beverage, and flavor industries. MycoTechnology has released ClearTaste, an all-natural, GMO-free, organic bitter blocker that is Kosher and Halalcertified. ClearTaste improves the flavor of various agricultural products.MycoTechnology also engages in fermenting agricultural products with strains of gourmet fungi. The company offers myceliated chocolate as well as robusta and arabica coffee beans. It develops and licenses technology to the industry to naturally improve the flavor of robusta and arabica coffee. The company was incorporated in 2013 and is based in Aurora, Colorado. | $42M | Series B | Aug 29, 2017 |  |
| Anaeropharma Science | Anaeropharma Science was established in 2004 to pioneer the development of novel therapeutics to target such a hypoxic environment in solid cancers based on its proprietary platform technology, recombinant bifidobacterium therapeutics. | $13.2M |  | Jul 05, 2017 |  |
| ENTEROME | Enterome is an integrated company leveraging its unique knowledge of the key functional and molecular interactions between the gut microbiome and the human body to develop targeted therapeutics.Enterome is focused on the identification of the bioactive molecules that are differentially expressed, secreted and regulated by the gut microbiome, whichplay a central role in the regulation of key aspects of human physiology and the immune system. | $35.1M | Series D | Jan 01, 2017 |  |
| ENTEROME | Enterome is an integrated company leveraging its unique knowledge of the key functional and molecular interactions between the gut microbiome and the human body to develop targeted therapeutics.Enterome is focused on the identification of the bioactive molecules that are differentially expressed, secreted and regulated by the gut microbiome, whichplay a central role in the regulation of key aspects of human physiology and the immune system. | $15.9M | Series C | Apr 20, 2016 |  |

8 of 8 investments shown.

## Co-investors
- [Seventure Partners](https://shizune.co/investors/profile/seventure-partners) — VC Fund, 6 deals together
- [Omnes Capital](https://shizune.co/investors/profile/omnes-capital) — VC Fund, 4 deals together
- [Lundbeckfonden Ventures](https://shizune.co/investors/profile/lundbeckfond-ventures) — VC Fund, 3 deals together
- Nestlé Health Science — VC Fund, 3 deals together
- [Principia SGR](https://shizune.co/investors/profile/quantica-sgr) — VC Fund, 3 deals together
- [Bristol-Myers Squibb](https://shizune.co/investors/profile/bristol-myers-squibb) — VC Fund, 2 deals together

## Similar investors

### Similar stage
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund
- [FJ Labs](https://shizune.co/investors/profile/fj-labs) — VC Fund

## FAQ

### What does Health for Life Capital fund invest in?

Health for Life Capital fund invests primarily in Biotechnology, Biopharma and Medical startups, most often at Series B and Series D stage. Most of the 8 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Health for Life Capital fund last invest?

The most recent investment recorded for Health for Life Capital fund closed in Jul 2021. Shizune tracks 8 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co